• Regeneron
    Retina/Vitreous

    Regeneron reported sales of $999 million for the second quarter, fueled by a 58% increase in year-over-year Eylea (aflibercept) sales.

    Net sales of Eylea in the United States increased from $415 million to $655 million, while net sales outside the country were $338 million, up from $247 million from the second quarter of 2014.